» Articles » PMID: 27310244

Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population

Overview
Specialty Psychiatry
Date 2016 Jun 17
PMID 27310244
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Although antidepressants and antipsychotics are valuable medications in the treatment of select psychiatric disorders, there is increasing focus on the balance of risks and benefits of these drugs as prescribed, particularly in the pediatric population. We examined recent national trends and interprovincial variation in dispensing of antipsychotic and antidepressant prescriptions to the Canadian pediatric population.

Method: We conducted a population-based cross-sectional study of antidepressant and antipsychotic prescriptions dispensed by Canadian pharmacies to the pediatric population (≤18 years) between 2010 and 2013. Prescription volumes were obtained from IMS Health. Analysis was stratified by drug, year, quarter, and province and population-standardized using age-adjusted population estimates.

Results: From the first quarter of 2010 to the fourth quarter of 2013, dispensing of antipsychotics to the pediatric population increased 33% (from 34 to 45 prescriptions per 1000) and dispensing of antidepressants increased 63% (from 34 to 55 per 1000). We observed a 1.5-fold interprovincial difference in dispensing rates for antidepressants (range: 189 per 1000 to 275 per 1000) and a 3.0-fold difference for antipsychotics (range: 85 per 1000 to 253 per 1000) in 2013. Among antidepressants, selective serotonin reuptake inhibitors were the most dispensed (76%), with fluoxetine being the leading agent. Among antipsychotics, atypical antipsychotics were the most dispensed (97%), with risperidone being the leading agent.

Conclusions: Antipsychotic and antidepressant dispensing to the Canadian pediatric population increased from 2010 to 2013, with considerable interprovincial variation. Future research is required to explore reasons for observed patterns to optimize care for the Canadian pediatric population.

Citing Articles

Association between a publicly funded universal drug program and antipsychotic and antidepressant medication dispensing to children.

Kitchen S, Gomes T, Tadrous M, Pajer K, Gardner W, Lunsky Y BMC Pediatr. 2025; 25(1):105.

PMID: 39923012 PMC: 11806594. DOI: 10.1186/s12887-024-05345-2.


Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study.

Antoniou T, McCormack D, Kitchen S, Pajer K, Gardner W, Lunsky Y BMC Public Health. 2023; 23(1):85.

PMID: 36631810 PMC: 9832754. DOI: 10.1186/s12889-022-14677-6.


Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol.

Menard M, Ilies D, Abadie P, Jean-Baptiste T, Choquette R, Huet A BMJ Open. 2021; 11(1):e040764.

PMID: 33455928 PMC: 7813300. DOI: 10.1136/bmjopen-2020-040764.


Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de....

Jazi S, Ben-Amor L, Abadie P, Menard M, Choquette R, Berthiaume C Can J Psychiatry. 2020; 66(7):645-656.

PMID: 33243011 PMC: 8243171. DOI: 10.1177/0706743720974847.


Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry.

Stip E, Javaid S, Bayard-Diotte J, Abdel Aziz K, Arnone D Ther Adv Psychopharmacol. 2020; 10:2045125320957118.

PMID: 32974000 PMC: 7493262. DOI: 10.1177/2045125320957118.


References
1.
Merikangas K, He J, Rapoport J, Vitiello B, Olfson M . Medication use in US youth with mental disorders. JAMA Pediatr. 2013; 167(2):141-8. DOI: 10.1001/jamapediatrics.2013.431. View

2.
Rani F, Murray M, Byrne P, Wong I . Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008; 121(5):1002-9. DOI: 10.1542/peds.2007-2008. View

3.
Emslie G, Ventura D, Korotzer A, Tourkodimitris S . Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry. 2009; 48(7):721-729. DOI: 10.1097/CHI.0b013e3181a2b304. View

4.
Kutcher S, Hampton M, Wilson J . Child and adolescent mental health policy and plans in Canada: an analytical review. Can J Psychiatry. 2010; 55(2):100-7. DOI: 10.1177/070674371005500206. View

5.
Cheung A, Emslie G, Mayes T . Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005; 46(7):735-54. DOI: 10.1111/j.1469-7610.2005.01467.x. View